CLVS - Clovis Oncology - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

Clovis Oncology's activity chart (see below) currently has 163 price targets and 125 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 56.35% with an average time for these price targets to be met of 81.22 days.

Most recent stock forecast was given by from HC WAINWRIGHT on 14-Jun-2022. First documented stock forecast 03-Jun-2014.

Best performing analysts who are covering CLVS - Clovis Oncology:

Madhu Kumar Thomas Shrader Cory Kasimov Peter Lawson Kennen Mackay

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 14-Jun-2022

4 years 4 months 5 days ago
(14-Jun-2022)

0/13 (0%)

$2.53 (172.11%)

Hold Since 30-Oct-2018

$4.75

$4.66 (5177.78%)

$5.75

4 years 11 months 16 days ago
(03-Nov-2021)

8/10 (80%)

$0.06 (1.28%)

66

Sell Since 20-May-2020

$3

$2.91 (3233.33%)

5 years 11 months 13 days ago
(06-Nov-2020)

3/5 (60%)

$-1.26 (-29.58%)

151

Buy Since 09-May-2018

$16

$15.91 (17677.78%)

$17

6 years 2 months 12 days ago
(07-Aug-2020)

4/11 (36.36%)

$10.58 (195.20%)

88

Sell Since 08-Oct-2019

6 years 5 months 13 days ago
(06-May-2020)

0/2 (0%)

$25.85 (43.70%)

Show more analysts

Please expand the browser size to see the chart

What is CLVS (Clovis Oncology) average time for price targets to be met?

On average it took 81 days for the stock forecasts to be reached, with an average price target met ratio of 56.35%.

Which analyst most recently updated their price target on CLVS (Clovis Oncology)?

Which analyst has the most public recommendations on CLVS (Clovis Oncology)?

has 0 price targets and 0 ratings on CLVS

Which analyst is the currently most bullish on CLVS (Clovis Oncology)?

Thomas Shrader with the highest potential upside of $124.91

Which analyst is the currently most reserved on CLVS (Clovis Oncology)?

Charles Duncan with the lowest potential downside of -$0
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?